Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) Q3 2024 Earnings Conference Call November 7, 2024 5:00 PM ET
Company Participants
Deb Hart – Head, Investor Relations
Trey Martin – Chief Executive Officer
Kevin Herde – EVP and Chief Financial Officer
Drew Burch – President, Nucleic Acid Production
Conference Call Participants
Dan Leonard – UBS
Justin Bowers – Deutsche Bank
Yuko Oku – Morgan Stanley
Matt Hewitt – Craig-Hallum
Dan Arias – Stifel
Operator
Good afternoon, ladies and gentlemen, and welcome, everyone, to the Maravai LifeSciences Third Quarter 2024 Earnings Conference Call. All lines have been placed on mute to prevent any background noise. After the speakerâ€s remarks, there will be a question-and-answer session. [Operator instructions]
Thank you. I would now like to turn the call over to Deb Hart. Please go ahead.
Deb Hart
Thank you. Good afternoon, everyone. Thanks for joining us on our third quarter 2024 earnings call. Our press release and the slides accompanying today’s call are posted on our website and available at investors.maravai.com.
As you can see from our agenda on Slide 2, Trey Martin, Chief Executive Officer; and Kevin Herde, Chief Financial Officer, are joining me today. Drew Burch, President of Nucleic Acid Production; and Becky Buzzeo, our Executive Vice President and Chief Commercial Officer, will join the call for the question-and-answer session following the prepared remarks.
We remind you that management will make forward-looking statements and refer to GAAP and non-GAAP financial measures during today’s call. It is possible that actual results could differ from management’s expectations.
We refer you to Slide 3 for more information about those forward-looking statements and our use of non-GAAP financial measures. Our just issued press release provides reconciliations to the most directly comparable GAAP measures. Please also refer to Maravai’s SEC filings for additional information on the risks and uncertainties that
